New CAR T Cell for Multiple Myeloma Approved by FDA
Ciltacabtagene autoleucel (cilta-cel) is indicated for patients with relapsed/refractory multiple myeloma who have already had many previous treatments.
FDA Approvals
source https://www.medscape.com/viewarticle/969380?src=rss
FDA Approvals
source https://www.medscape.com/viewarticle/969380?src=rss
Comments
Post a Comment